Transaction in Own Shares

BioPharma Credit PLC

10 January 2024

 

BioPharma Credit plc

(the "Company")

TRANSACTION IN OWN SHARES

BioPharma Credit PLC (the "Company") announces that on 9 January 2024, it purchased the following number of its ordinary shares of US$0.01 each on the London Stock Exchange through J.P. Morgan Securities plc into treasury.

Ordinary Shares: BPCR LN

Date of purchase: 9 January 2024

Number of ordinary shares purchased: 56,295

Lowest price per share: $0.9340

Highest price per share: $0.9340

Trading venue: London Stock Exchange

Ordinary Shares: BPCR LN

Date of purchase: 9 January 2024

Number of ordinary shares purchased: 600,000

Lowest price per share: $0.9340

Highest price per share: $0.9340

Trading venue: JPSI

Aggregate volume per date per trading venue: 656,295

Weighted average price per day per trading venue: $0.9340

Following the above transaction, the Company holds 74,270,232 of its ordinary shares in treasury and has 1,299,661,835 ordinary shares in issue (excluding treasury shares). Therefore, the total number of voting rights in the Company is 1,299,661,835. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

[phone]

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

[phone]

[e-mail]

Notes to Editors:

BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24

 

END